Factors influencing the response of MCF-7 cells to an agonist of luteinising hormone-releasing hormone.
To clarify the mechanism by which the luteinising hormone-releasing hormone agonist, buserelin, may have direct effects on breast cancer cells, factors potentially influencing its action have been studied in the MCF-7 breast cancer cell line. Oestradiol and epidermal growth factor (EGF), which stimulate the growth of MCF-7 cells in culture, reversed, at least in part, the inhibitory effects of buserelin. Insulin also abolished growth inhibition. Quantitative effects of buserelin differed according to the batch of fetal calf serum used as media supplement. These data suggest that the direct inhibitory effects of buserelin on breast cancer cells are mediated at least in part by an antagonism of growth-promoting factors.
Scott
W N
WN
Imperial Cancer Research Fund, Western General Hospital, Edinburgh, U.K.
Mullen
P
P
Miller
W R
WR
D001943:Breast Neoplasms / Q000188:drug therapy*; D002064:Buserelin / Q000037:antagonists & inhibitors / Q000627:therapeutic use*; D002460:Cell Line; D003470:Culture Media; D004815:Epidermal Growth Factor / Q000494:pharmacology; D004958:Estradiol / Q000494:pharmacology; D005260:Female; D007987:Gonadotropin-Releasing Hormone / Q000502:physiology*; D006801:Humans; D007328:Insulin / Q000494:pharmacology; D014407:Tumor Cells, Cultured / Q000187:drug effects
D003470:Culture Media; D007328:Insulin; D007987:Gonadotropin-Releasing Hormone; D004958:Estradiol; D004815:Epidermal Growth Factor; D002064:Buserelin